Health X Platform Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹346Cr
- +23.1% YoY
- +15% QoQ
- Net profit
- ₹0Cr
- Q3 FY25: −₹38 Cr
- Margin
- −3%
- +5 pp YoY
- +5 pp QoQ
Guidance rank: #1 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Retailer Shakti aims to grow at a CAGR of +30% year-on-year for the next 5-10 years, with some quarter-to-quarter variability. Retailer Shakti is progressing towards EBITDA break-even by Q4 FY26 and expected to deliver sustainable EBITDA positive performance in FY27, with anticipated 1% EBITDA margin.
From Health X Platform Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Retailer Shakti aims to grow at a CAGR of +30% year-on-year for the next 5-10 years, with some quarter-to-quarter variability.
- SastaSundar B2C business is expected to grow around 100% year-on-year from this year to next.
- January to March is expected to be one of the best quarters, with recent growth trends positive.
- Expansion plans include new warehouses in Lucknow, Udaipur, and capacity doubling in existing facilities to support growth across Eastern, Northern, and North-Eastern India.
- The JITO generic brand is projected to significantly increase revenue and gross margin by tapping into a rapidly growing generic medicine market.
2 more points from Health X Platform Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Health X Platform Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Investing ~Rs. 10 crores in West Bengal for an additional 80,000 sq ft warehouse capacity (completion in ~6 months).
- Planning a new warehouse in Noida; timeline about 1.5 years; also expansions in Guwahati, Lucknow, Udaipur (2-year horizon).
- Allocated Rs. 25 crores annually for AI and technology development for both SastaSundar and Retailer Shakti platforms.
- Rs. 150 crores earmarked for new technology building, with Rs. 50-60 crores already spent; remaining to be funded from treasury income over next 2-3 years.
- Rs. 10 crores invested in Retail Air, an AI-driven SaaS platform for retailers, to be launched in 3-4 months.
2 more points from Health X Platform Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Health X Platform Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Health X Platform Ltd's call on order book
Create a free account to keep reading this call
Health X Platform Ltd — Quarterly revenue & net profit
Health X Platform Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 346 | 281 | +23.1% | 301 | +15% |
| Operating profit (EBITDA) | -10 | -24 | — | -23 | — |
| Operating margin | -3% | -8% | +5 pp | -8% | +5 pp |
| Profit before tax | 1 | -39 | — | -19 | — |
| Net profit (PAT) | 0 | -38 | — | -15 | — |
| EPS (₹) | 0.36 | -8.47 | — | -3.99 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹484 Cr, net loss ₹13 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Health X Platform's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- 1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Health X Platform Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Health X Platform Ltd Q3 FY26 results?
Retailer Shakti aims to grow at a CAGR of +30% year-on-year for the next 5-10 years, with some quarter-to-quarter variability. Retailer Shakti is progressing towards EBITDA break-even by Q4 FY26 and expected to deliver sustainable EBITDA positive performance in FY27, with anticipated 1% EBITDA margin.
What is Health X Platform Ltd share price analysis?
Health X Platform Ltd currently shows a neutral. The stock trades at a P/E of 508.6 with a market cap of ₹977 Cr. Investors should review the full earnings analysis for detailed insights.
Is Health X Platform Ltd planning capital expenditure?
Investing ~Rs. 10 crores in West Bengal for an additional 80,000 sq ft warehouse capacity (completion in ~6 months).
Keep Health X Platform Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
